Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis

Table 4

Gene-set analysis of raloxifene response at femoral neck site.

Database	Pathway	Number of genes	Beta	SE	value	value
GO bp	Platelet morphogenesis	16	0.762	0.208		0.859
GO bp	Regulation of nuclear transcribed mrna catabolic process deadenylation-dependent decay	14	0.633	0.187		0.859
GO bp	Cellular modified amino acid catabolic process	17	0.616	0.185		0.859
Curated gene sets	Osteoblast differentiation by phenylamil up	12	0.779	0.234		0.859
GO bp	Regulation of pri mirna transcription from rna polymerase ii promoter	16	0.691	0.209		0.859
GO bp	Regulation of establishment of protein localization to mitochondrion	118	0.234	0.073		0.966
GO bp	Regulation of protein targeting to mitochondrion	89	0.266	0.083		0.966
Curated gene sets	Werner syndrome and normal aging up	91	0.251	0.08		0.991
Curated gene sets	Aml methylation cluster 6 dn	32	0.418	0.137		0.999
GO bp	Epithelial structure maintenance	21	0.559	0.184		0.999
GO bp	Regulation of substrate adhesion-dependent cell spreading	41	0.379	0.129		0.999
Curated gene sets	Proteolytic cleavage of snare complex proteins	16	0.752	0.26		0.999
GO bp	Cardiac myofibril assembly	16	0.574	0.204		0.999
GO bp	Positive regulation of pri mirna transcription from rna polymerase ii promoter	10	0.702	0.25		0.999
Curated gene sets	Botulinum neurotoxicity	18	0.674	0.241		0.999
GO bp	Negative chemotaxis	38	0.391	0.142		0.999
GO bp	Regulation of endocrine process	44	0.348	0.126		0.999
Curated gene sets	Chondroitin sulfate biosynthesis	17	0.507	0.184		0.999
GO bp	Cellular metabolic compound salvage	35	0.36	0.131		0.999
GO bp	Cytokinesis	80	0.246	0.09		0.999

GO: gene ontology; bp: biological process; values were from false discovery rate.